Hollywood Man Gets 5 Years for Filing Bogus Claims for COVID-Related Tax Credits
A federal judge
Kevin J. Gregory, 57, was sentenced by U.S. District Judge Josephine Staton, who also ordered him to pay nearly $2.8 million in restitution.
Gregory pleaded guilty on Jan. 17 to one count of making false claims to the Internal Revenue Service (IRS). He has remained in federal custody since May 2023, according to prosecutors.
In March 2020, Congress authorized an
The credit was designed to encourage businesses to keep paying their employees during the pandemic.
Any business, regardless of size, could qualify for the tax credit if it had been operating in 2020 and was at least partially suspended because of a government order related to the pandemic, or had seen a decline in revenue of more than 50 percent.
Related Stories
5/26/2023
1/10/2025
Qualifying businesses received 50 percent of up to $10,000 in wages paid by an employer between March 13 and Dec. 31, 2020, according to the U.S. Treasury Department.
Congress also authorized a 'paid sick and family leave credit' during the pandemic that authorized the IRS to give a credit to businesses for wages paid to workers who were on sick or family leave and couldn't work because of COVID-19.
According to federal prosecutors, Gregory made false claims to the IRS for the payment of nearly $65.3 million in tax refunds from November 2020 to April 2022.
The refunds were for a Beverly Hills-based farming-and-transportation company named Elijah USA Farm Holdings, which did not exist.
Federal prosecutors say the IRS issued a portion of the refunds Gregory claimed, and he used more than $2.7 million for personal expenses.
In January 2022, Gregory filed a false claim to the IRS for a tax refund in the amount of $23.8 million, which he submitted as part of Elijah Farm's quarterly federal tax return, according to prosecutors.
He claimed in his filing that Elijah Farm employed 33 people, paid nearly $1.6 million in quarterly wages, and had deposited nearly $18 million in federal taxes.
'In fact, Gregory knew that Elijah Farm employed nobody and paid wages to no one and had not made federal tax deposits to the IRS in the amounts stated on his tax return,' the U.S. Attorney's Office stated in a press release Thursday.
Gregory was
The statutory maximum sentence for the charges was five years in federal prison. Gregory was sentenced to 57 months in prison—just under the maximum.
The IRS's criminal investigation unit handled the case, and Assistant U.S. Attorney Kristen Williams of the major frauds section prosecuted it.
Gregory could not be reached for comment.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030
Antibody discovery, crucial for developing targeted therapies in fields like oncology and autoimmune diseases, is evolving with innovations like phage display and AI-driven design. The market is booming across North America, Europe, and Asia-Pacific, driven by personalized medicine and rapid advancements in antibody discovery technologies. Antibody Discovery Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Antibody Discovery - Global Strategic Business Report" has been added to global market for Antibody Discovery was valued at US$1.9 Billion in 2024 and is projected to reach US$3.3 Billion by 2030, growing at a CAGR of 9.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Antibody Discovery market. Why Is Antibody Discovery at the Forefront of Next-Generation Therapeutic Development?Antibody discovery is emerging as a cornerstone of modern drug development, driven by the escalating demand for targeted therapies across oncology, autoimmune disorders, infectious diseases, and rare conditions. Monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs) are transforming clinical outcomes through their high specificity, tunable pharmacokinetics, and ability to engage or inhibit precise molecular targets. The discovery phase - encompassing target identification, antibody generation, screening, and lead optimization - is critical to ensuring downstream therapeutic efficacy, safety, and commercial viability. As biopharmaceutical pipelines increasingly prioritize biologics over small molecules, antibody discovery is becoming an indispensable gateway to innovation.A significant driver of this trend is the surge in demand for personalized medicine and immunotherapy, where antibody-based therapeutics are used to modulate immune response, block disease-associated pathways, or deliver cytotoxic payloads directly to tumor cells. The urgency created by the COVID-19 pandemic further underscored the importance of rapid antibody discovery, as neutralizing antibodies became pivotal in the therapeutic and diagnostic response to SARS-CoV-2. Global interest in therapeutic antibodies is prompting pharmaceutical and biotech firms to accelerate discovery programs using faster, more predictive, and less immunogenic methods. As the market shifts from traditional hybridoma techniques to humanized platforms and next-gen in silico approaches, antibody discovery is positioned at the heart of biopharma R&D strategies Are Technological Innovations Accelerating Discovery Timelines and Improving Lead Quality?Cutting-edge technologies are reshaping every stage of the antibody discovery process, enabling faster identification of high-affinity, developable antibodies with favorable safety and manufacturability profiles. Phage display and yeast display platforms have largely replaced traditional hybridoma-based generation, offering vast diversity libraries and rapid selection capabilities. More recently, microfluidics, single B-cell screening, and high-throughput sequencing have revolutionized early-stage discovery by capturing naturally occurring antibody repertoires from immunized animals or convalescent human donors. These tools enable the isolation of rare, highly potent antibodies that would otherwise go undetected through conventional biology and AI-driven design are also transforming the discovery pipeline by predicting binding affinity, stability, immunogenicity, and epitope specificity in silico. Machine learning algorithms are being trained on large antibody datasets to accelerate lead optimization, reduce experimental trial-and-error, and improve success rates in later development phases. Humanization techniques - ranging from chimerization to full deimmunization - are being refined to enhance safety and reduce rejection risk. Additionally, CRISPR/Cas9 and transgenic animal models are being leveraged to generate fully human antibodies with precise specificity. These technology integrations are enabling rapid, scalable, and cost-efficient antibody discovery workflows that meet the high standards of regulatory and therapeutic Is Market Demand Rising and Which Therapeutic Areas Are Driving Discovery Investment?Market demand for antibody discovery services and platforms is rising sharply across North America, Europe, and Asia-Pacific, where biopharma companies, academic labs, and contract research organizations (CROs) are intensifying efforts to expand antibody-based pipelines. The U.S. leads in therapeutic antibody development, backed by significant biotech investment, advanced research infrastructure, and regulatory support for expedited biologic approvals. Europe, particularly Germany, Switzerland, and the U.K., is seeing strong growth in CRO-based discovery partnerships and academic spinouts. Meanwhile, Asia-Pacific - especially China, South Korea, and Japan - is becoming a major hub for antibody innovation, fueled by state-backed biotech programs, growing clinical trial activity, and rapid commercialization remains the largest and fastest-growing therapeutic segment for antibody discovery, accounting for the majority of pipeline activity in monoclonal and bispecific antibodies. Immuno-oncology applications, such as checkpoint inhibitors and T-cell engagers, are expanding rapidly with significant investment in PD-1/PD-L1, CTLA-4, CD3, and CD20 targets. Autoimmune and inflammatory diseases - including rheumatoid arthritis, psoriasis, and Crohn's disease - also represent major discovery areas, with antibody candidates aimed at cytokines and immune receptors such as IL-6, TNF-alpha, and IL-17. Infectious disease research continues to drive antibody discovery in the wake of COVID-19, with new programs targeting HIV, RSV, and influenza. Rare and neurological diseases, including ALS, Alzheimer's, and neuromyelitis optica, are emerging as high-value niches for precision antibody therapies. These diverse and expanding indications are propelling sustained investment and innovation in antibody discovery workflows across Is Fueling the Growth of the Global Antibody Discovery Market?The growth in the antibody discovery market is driven by several factors, including the rising prevalence of chronic and rare diseases, expansion of biologics pipelines, and breakthroughs in molecular screening and AI-assisted drug design. A central driver is the therapeutic success of antibodies already in the market - such as trastuzumab, adalimumab, and pembrolizumab - which continue to demonstrate the clinical and commercial potential of antibody-based drugs. The robust deal activity between pharmaceutical giants and antibody discovery specialists is further catalyzing growth, as companies seek early access to differentiated platforms and promising outsourcing by biotech startups and mid-sized firms is also fueling market demand for discovery-as-a-service models, where CROs and specialized technology vendors provide end-to-end discovery capabilities from antigen design to humanized lead delivery. Advances in automation, sequencing, and data analytics are lowering the cost per discovery while improving success predictability, making antibody R&D more accessible to smaller players. Moreover, government and institutional funding for pandemic preparedness, cancer immunotherapy, and biosimilar development are boosting both public and private sector involvement. As antibody therapeutics become increasingly central to precision medicine and immune modulation, a crucial question emerges - can antibody discovery platforms keep pace with the clinical complexity and specificity required for next-generation, globally accessible biologic treatments?Report ScopeThe report analyzes the Antibody Discovery market, presented in terms of market value (US$ Thousand). The analysis covers the key segments outlined Antibody Type (Monoclonal, Polyclonal, Other Antibody Types) Service (Phage Display, Hybridoma, Other Services) End-Use (Pharmaceutical & Biotechnology Companies, Research Laboratories, Other End-Uses) Key Insights: Market Growth: Understand the significant growth trajectory of the Monoclonal Antibody segment, which is expected to reach US$2 Billion by 2030 with a CAGR of a 9.3%. The Polyclonal Antibody segment is also set to grow at 10.9% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $500.0 Million in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $530.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abcam, AbCellera Biologics, Ablexis, Adimab, Akeso Biopharma and more. Tariff Impact Analysis: Key Insights for 2025Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments and incorporates forward-looking insights into the market analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities. Key Attributes: Report Attribute Details No. of Pages 224 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.9 Billion Forecasted Market Value (USD) by 2030 $3.3 Billion Compound Annual Growth Rate 9.8% Regions Covered Global Key Topics Covered: MARKET OVERVIEW World Market Trajectories Antibody Discovery - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Demand for Precision Biologics Spurs Innovation Across the Antibody Discovery Landscape AI-Driven Screening Platforms Shorten Discovery Timelines for Therapeutic Antibodies Next-Generation Sequencing and Single-Cell Tools Redefine Antibody Target Identification CRO Partnerships Accelerate Outsourced Antibody Discovery Among Biopharma Firms Oncology and Autoimmune Therapies Dominate the Clinical Focus of Antibody Discovery Pipelines Transgenic Animal Models Expand the Scope of Novel Antibody Generation Bispecific and Monoclonal Advances Unlock Complex Disease Targeting in Antibody Discovery Data Integration Across Platforms Enhances Efficiency in Antibody Optimization Collaborations with Academia Infuse Innovation into Antibody Discovery Frameworks Expiry of Biologic Patents Opens New Pathways for Biosimilar Antibody Development Regulatory Support for First-in-Class Biologics Encourages Bold Innovation in Discovery End-to-End Platform Integration Strengthens the Commercial Value Chain in Antibody Discovery FOCUS ON SELECT PLAYERSSome of the 41 companies featured in this Antibody Discovery market report include: Abcam AbCellera Biologics Inc. Ablexis Adimab Akeso Biopharma Biocytogen Pharmaceuticals Co., Ltd. Bruker Corporation Charles River Laboratories ChemPartner Creative Biolabs Danaher Corporation Eurofins Scientific Evotec SE FairJourney Biologics Genmab GenScript Biotech Corporation Harbour BioMed Icosagen AS ImmunoPrecise Antibodies Ltd. Isogenica Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Discovery Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
ScotRail news, interviews and updates on the railway operator
Scotrail is a publicly owned, nationalised rail service operated on by The Scottish Government and overseen by Scottish Rail Holdings Limited. The train service was returned to public ownership in April 2022 after The Scottish Government ended its ten-year contract with Abellio three years early. The Dutch state-owned railway company had been awarded the franchise in 2015 to run until 2025, but the deal was cut short following criticism over cancellations and performance. The contract was worth more than £7 billion, according to the BBC. Read on for all the latest ScotRail news, interviews and updates. As reported by The Herald, here is a selection of the latest ScotRail news stories. Scot Gov declines to reveal cost of Intercity bids process ScotRail warning ahead of Far North Line improvement works ScotRail: Glasgow Central trains face disruption amid issue On-peak travel is generally between 06:00 and 09:15, and 16:30-18:00. Always check with ScotRail before you travel to ensure you have the correct ticket. John Swinney announced the peak train fares in Scotland will be scrapped permanently from from September 1 2025. The First Minister confirmed the policy at Holyrood, following a pilot scheme that removed peak-time ScotRail fares but ended in September last year following 'limited success'. Transport Scotland said the scheme - which was subsidised by the Scottish Government and standardised tickets across the day - 'did not achieve its aims' of persuading more people to car journeys for rail travel. ScotRail's off-peak tickets can be used after 9.15am on weekdays, and at any time on the weekend and on Scottish bank holidays. Some evening travel restrictions apply to off-peak tickets depending on the station or route. Always check with ScotRail before you travel to ensure you have the correct ticket (Image: Archive) The ban on drinking alcohol on ScotRail services is set to come to an end. First Minister John Swinney made the announcement when he made his Programme for Government statement to Holyrood. The document said the ban is 'counter-productive and ineffective'. A press release from the Scottish Government, which also announced the ending of peak train fares, said: "ScotRail peak rail fares abolished and the general alcohol ban on ScotRail trains removed and replaced with time and location restrictions." A blanket ban on drinking alcohol on ScotRail trains was introduced during Covid-19 in November 2020 and was extended 'for the foreseeable future' in 2022. The 24/7 ban prohibited drinking alcohol at any Scottish station or on any ScotRail service. Transport union RMT said ScotRail's ban cannot be 'adequately enforced', and has called on the train operator to tackle anti-social behaviour. The alcohol ban on ScotRail services has been around since November 2020 (Image: Newsquest) Gordon Martin, organiser at RMT Scotland, told The Herald: "It is not the job of rail workers to police the anti-social behaviour of passengers, and it is clear the rules around alcohol consumption cannot be adequately enforced. "What we need is for ScotRail to take real responsibility for dealing with anti-social and violent conduct, and to ensure every assault on staff is treated seriously and prosecuted to the full extent of the law." Domestic pets, such as dogs, cats, or tortoises, are allowed on ScotRail train services. According to the operator's website, up to two pets are allowed, but they must be on a lead or in a travel cage. ScotRail has options for frequent travellers to save money. Train season tickets offer a 40 per cent saving for those commuting five days a week. There are weekly, monthly, or annual options for the Season Tickets. With the removal of peak fares, season tickets were discounted by 20 per cent for a year and that will continue as planned until September. ScotRail say Flexipass provides a 30 per cent discount, allowing 12 single or six return journeys on the same route within 60 days. More information on ScotRail's railcards and tickets is available on its website. ScotRail passengers experiencing delays of 30 minutes or more could be entitled to compensation. This also applies to missed connections caused by ScotRail train delays. Claims must be made within 28 days of the delay.
Yahoo
an hour ago
- Yahoo
Vodafone and Three merge to become Britain's biggest mobile network
Vodafone and Three have vowed to improve Britain's patchy 5G coverage after completing their long-awaited £15bn mega-merger. The two companies said they have closed the deal to create VodafoneThree, which is now the UK's largest mobile network operator with around 27m customers. Bosses said VodafoneThree will invest £11bn over the next decade to create one of Europe's most advanced 5G networks. This includes a £1.3bn capital expenditure pledge in the first year. Margherita Della Valle, chief executive of Vodafone Group, said: 'The merger will create a new force in UK mobile, transform the country's digital infrastructure and propel the UK to the forefront of European connectivity. 'We are now eager to kick off our network build and rapidly bring customers greater coverage and superior network quality. The transaction completes the reshaping of Vodafone in Europe, and following this period of transition we are now well-positioned for growth ahead.' It comes two years after Vodafone and Three owner CK Hutchison, which is owned by the Hong Kong billionaire Li Ka-Shing, first announced plans to merge their UK operations. The deal has been held up by a lengthy regulatory process amid concerns reducing the number of UK mobile network operators from four to three would push up prices for consumers. Unions and China-sceptic MPs also raised concerns about granting Hong Kong-based CK Hutchison access to critical national infrastructure and sensitive government contracts. However, the deal passed a national security review and in December the Competition and Markets Authority gave the green light to the merger. Vodafone and Three have made a number of legally-binding commitments, including the £11bn investment pledge and guarantees around some consumer tariffs. More recently, the launch has been delayed by negotiations between Vodafone and CK Hutchison over the terms of the deal. The newly-merged company will be 51pc owned by Vodafone, while Three will hold the remaining 49pc. Vodafone has an option to buy out Three's stake after three years. It will be led by Max Taylor, current chief executive of Vodafone UK, while Three's Darren Purkis has been appointed chief financial officer. Bosses said the combined company is expected to deliver cost savings of around £700m per year, unlocking more money for network investment. VodafoneThree's net debt is expected to be £6bn and the parent companies have agreed to contribute £800m of equity to support working capital requirements. Canning Fok, deputy chairman of CK Hutchison, said: 'As we have demonstrated in other European markets, scale enables the significant investment needed to deliver the world-beating mobile networks our customers expect, and the Vodafone and Three merger provides that scale. 'In addition, this transaction unlocks significant shareholder value, returning approximately £1.3bn in net cash to the group.'
